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Summary
Background.— Cystatin C, which has long been regarded as a biomarker that indicates kidney
functions, has recently been recognized as an inﬂammatory marker in the human body.
Aim.— To elucidate how cystatin C is related to the prognosis of systolic heart failure patients.
Methods.— Patients with systolic heart failure who were admitted to the fourth afﬁliated hos-
pital of Harbin Medical University between January and April 2008 were enrolled in this study.
Serum homocysteine, high-sensitivity C-reactive protein (hs-CRP) and cystatin C levels were
determined and all the patients received an average of 2 years of follow-up for occurrence of
death, heart transplantation or readmission with worsening heart failure.
Results.— Of 138 patients enrolled, those who experienced adverse outcomes (e.g. cardiac
death, heart transplantation or progressive heart failure) (n = 21) had considerably higher mean
levels of serum homocysteine (28.6± 13.4 vs 14.4± 6.3mg/L; P < 0.01), hs-CRP (17.5± 14.1
vs 6.4± 7.7mol/L; p < 0.01) and cystatin C (1.63± 0.81 vs 0.91± 0.27mg/L; P < 0.01) than
those without adverse outcomes (n = 117). Furthermore, the Cox proportional hazards model
demonstrated that serum homocysteine, hs-CRP and cystatin C are all independent predictors
of adverse outcomes.
Conclusions.— Cystatin C, together with hs-CRP and homocysteine, is an independent risk factor
that is important in the prognosis of patients with systolic heart failure.
© 2011 Elsevier Masson SAS. All rights reserved.
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cardiaque ;
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CRP ultra sensible ;
Cystatine C
Résumé
Objectifs.— La cystatine C est un biomarqueur d’évaluation de la fonction rénale, habituel-
lement évalué par la créatinine mais a été considéré récemment comme un marqueur de
l’inﬂammation chez l’homme. Cependant, la relation entre taux de cystatine C et pronostic
de l’insufﬁsance cardiaque reste non élucidée.
Méthode.— Cent trente-huit patients, insufﬁsants cardiaques, admis à l’hôpital Harbin en 2008,
ont été inclus dans l’étude. Les taux sériques d’homocystéine, de CRPus et de cystatine C ont
été mesurés chez tous les patients, qui ont été suivis pendant une durée moyenne de deux
ans, avec prise en considération des évènements suivants : décès, transplantation cardiaque et
réadmission pour aggravation de l’insufﬁsance cardiaque.
Résultats.— Les patients ayant présenté une complication avaient des taux signiﬁcative-
ment plus élevés d’homocystéine sérique, de CRPus et cystatine C comparativement
aux patients n’ayant pas présenté d’évènement cardiovasculaire (taux d’homocystéine
28,6± 13,4 versus 14,4± 6,3mg/l, p < 0,01 ; CRPus 17,5± 14,1 versus 6,4± 7,7, p < 0,01 ; cys-
tatine C 1,63± 0,81 versus 0,91± 0,27mg/L, p < 0,01). De plus, le modèle de Cox a montré que
les taux sériques et d’homocystéine, de CRPus et de cystatine C étaient tous des prédicteurs
indépendants de la survenue de complications cardiovasculaires.
Conclusion.— La cystatine, ainsi que la CRPus et l’homocystéine sont des prédicteurs indépen-
dants d’évènements cardiovasculaires et sont associés au pronostic chez les patients insufﬁsants
cardiaques.
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bbreviations
CE angiotensin-converting enzyme
RB angiotensin receptor blocker
NP B natriuretic peptide
I conﬁdence interval
DL high-density lipoprotein
R hazard ratio
s-CRP high-sensitivity C-reactive protein
DL low-density lipoprotein
VEF left ventricular ejection fraction
T-ProBNP N-terminal prohormone brain natriuretic pep-
tide
YHA New York Heart Association
ackground
eart failure is the end stage of heart disease. It is usu-
lly irreversible, and is characterized by high mortality. The
ethods used to treat or manage heart failure (such as
eart transplantation and stem-cell transplantation) have
nly limited effects [1], indicating that heart failure does
ot merely cause damage to the heart, but that it is a
ystematic disease. For this reason, the above-mentioned
ethods cannot represent a complete cure. In the past two
ecades, scholars have realized that oxidative stress is one
f the most important causes of heart failure because the
iomarkers of oxidative stress are extremely high in patients
uffering from heart failure compared to healthy individ-
als [2—8]. Furthermore, treatments focused on oxidative
tress can relieve symptoms and increase the cardiac func-
ion in both heart failure patients and animal models [9—12].
he levels of these biomarkers are thought to be highly
aluable for the evaluation of the severity of heart fail-
re and the effectiveness of treatments. Such biomarkers
h
d
p
as droits réservés.
nclude thiobarbituric acid-reactive substances and 8-iso-
rostaglandin F2alpha [2,13].
Cystatin C is one of the most frequently studied biomark-
rs that indicate the level of oxidative stress in the human
ody; and is closely related to heart disease. Lee et al. found
hat patients with coronary artery disease exhibit increased
erum cystatin C levels [14]. The same observation is evi-
ent among patients with hypertension [15]. However, the
anner by which cystatin C is related to systolic heart fail-
re and its prognosis remains unknown. We hypothesized
hat patients experiencing systolic heart failure would have
igher cystatin C levels, and that cystatin C exhibits an
nverse relationship with the prognosis of systolic heart fail-
re. We therefore measured cystatin C levels in patients
ith systolic heart failure. We also followed these patients
or an average of 2 years to verify our hypothesis.
ethods
tudy population
onsecutive patients with either chronic or new-onset
ystolic heart failure (effort dyspnoea or echocardiographic
ndings of systolic dysfunction) who were admitted to our
ospital between January and April 2008 were screened
or inclusion into this prospective study. The signiﬁcance
f heart failure was determined by both echocardiography
nd NYHA classiﬁcation. Only patients who successfully
nderwent serum hs-CRP, homocysteine and cystatin C
easurements besides regular examinations (e.g. blood
est, echocardiogram, electrocardiogram, etc.) qualiﬁed
or inclusion. Exclusion criteria included signiﬁcant valvular
eart disease, active myocarditis, known congenital heart
isease, recent acute coronary syndrome (within 6 months),
ending revascularization, uncontrolled hypertension,
nd/or signiﬁcant endocrine, hepatic, renal or inﬂammatory
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disease. All female patients were postmenopausal and not
taking any hormone replacement therapy.
Left ventricular ejection fraction
The Vivid 7 color Doppler ultrasonic (GE Healthcare, Shang-
hai, China) was used for the evaluation of cardiac function.
The left ventricular endocardial borders were recorded
from the projected left ventriculogram in end systole and
diastole. Ejection fractions of patients were conﬁrmed by
echocardiographic assessment.
Laboratory tests
After an overnight fast (≥ 12 h), blood samples were
obtained from all patients after bed rest for 15min in a quiet
room in the morning hours before enrolment as described
previously [16]. Homocysteine, hs-CRP, cystatin C, total
serum bilirubin, total cholesterol, triglycerides, LDL and HDL
were measured and recorded for analysis.
Long-term follow-up
All patients underwent long-term follow-up. Periodical phys-
ical examinations were performed every 3months either
at home or in the hospital. Blood tests were performed
at the same time. To achieve a maximum follow-up dura-
tion of 3 years, vital signs (blood pressure and heart rate)
were determined for all enrolled patients as of April 2008.
During long-term follow-up, the adverse outcomes deﬁned
as primary endpoints were: (1) death from cardiac causes
(deﬁned as sudden cardiac death or death resulting from
progressive pump failure); (2) development or progression
of heart failure that required hospitalization for an intra-
venous treatment of heart failure within the ﬁrst 3 days
after admission; or (3) heart transplantation. For patients
experiencing > 1 adverse outcome, only the ﬁrst one was
considered. All information regarding potential adverse out-
comes was acquired by review of source data, including
hospital record forms, death certiﬁcates and other original
documents. Other vascular events, such as stroke, nonfatal
myocardial infarction or coronary revascularization, were
also assessed, but not included into the outcome analy-
sis. Medical therapy, including ACE inhibitors, angiotensin
receptor blockers, beta-blockers and lipid-lowering drugs
was documented.
Statistics analysis
SPSS 17.0 software was used to analyze the data. Results
are reported as group means± standard deviation (SD). A
one-way ANOVA was used to determine differences among
the group means. Differences at P < 0.05 were considered
signiﬁcant. Cumulative adverse outcome rates were esti-
mated by Kaplan-Meier survival curves and compared by the
log-rank test. For survival analysis, patients were split into
two groups, based on the median values, for each of serum
homocysteine, hs-CRP and cystatin C. Cox proportional haz-
ards regression analysis was used to analyze follow-up data.
Among all the variables tested, only those with statisti-
cal signiﬁcance set at P < 0.05 at univariate analysis were
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ncluded in a multivariable Cox regression model to deter-
ine independent predictors of adverse outcomes.
esults
atient characteristics
f 168 patients screened, 138 met the inclusion criteria and
ad complete clinical data. The mean follow-up time was
years (range 0.3—3 years). During follow-up, 32 adverse
utcomes in 21 patients were documented: 10 patients died
f cardiac causes (seven sudden death and three refractory
eart failure); two patients received heart transplantation
nd survived until the end of follow-up; and nine had exacer-
ation of heart failure as observed in the worsening of NYHA
unctional class and required re-hospitalization and intra-
enous treatment for heart failure. Eleven patients suffered
rom one adverse outcome, nine patients from two adverse
utcomes, one from three adverse outcomes. No patients
ied of non-cardiac causes.
Patient characteristics and clinical outcomes are shown
n Table 1. The proportion of patients receiving pharmaco-
ogical agents such as ACE inhibitors, ARBs, beta blockers,
igoxin and statins did not differ signiﬁcantly among the
roups with and without adverse outcomes.
ifferences in serum homocysteine, hs-CRP
nd cystatin C levels between the two groups
he serum levels of homocysteine, hs-CRP, and CysC were
etermined. As shown in Table 1, patients experienc-
ng adverse outcomes had a signiﬁcantly higher level of
omocysteine than did those without adverse outcomes
28.6± 13.4 vs 14.4± 6.3; P < 0.001). Similar results were
een for hs-CRP levels (17.5± 14.1 vs 6.4± 7.7; P < 0.001)
nd cystatin C levels (1.63± 0.81 vs 0.91± 0.27mg/L;
< 0.001) (Table 1).
ystatin C was an independent predictor in
atients with heart failure
urther analysis was carried out to determine how cystatin C
nd other factors are associated with the prognosis of heart
ailure patients. In this study, we also found that homocys-
eine was another independent risk factor in the prognosis of
ystolic heart failure patients. In the univariate Cox regres-
ion analysis (Table 2), male gender, history of hypertension,
ower triglycerides, and higher serum creatinine, homocys-
eine, hs-CRP and cystatin C levels were all signiﬁcantly
elated to poor prognosis among patients with systolic heart
ailure. In the subsequent multivariate analysis, only triglyc-
rides, homocysteine, hs-CRP and cystatin C levels showed
signiﬁcant relationship with prognosis (Table 3).
atients with higher cystatin C levels had a
igher rate of adverse outcomeshen comparing adverse outcomes among patients with low
ersus high biomarker levels, the cutoff points were chosen
s the medians of the entire spectrum (0.9mg/L for cystatin
; 4.2mol/L for hs-CRP and 14mg/L for homocysteine)
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Table 1 Characteristics of patients with and without adverse outcomes.
All patients
(n = 138)
Patients without
adverse outcomes
(n = 117)
Patients with
adverse outcomes
(n = 21)
Age (years) 65.4± 11.0 64.1± 11.2 72.5± 5.4
Men 74 (54) 60 (51) 14 (67)
LVEF (%) 46.8± 8.1 48.0± 7.8 39.7± 5.4
Diagnosis
Ischaemic heart disease 60 (43) 48 (41) 12 (57)
DCMP 78 (57) 69 (59) 9 (43)
History of hypertension 81 (59) 68 (58) 13 (62)
Diabetes mellitus 33 (24) 30 (26) 3 (14)
Atrial ﬁbrillation 68 (49) 54 (46) 14 (67)
Laboratory results
Creatinine (mol/L) 82.0± 37.1 77.5± 29.2 109.3± 61.7
Uric acid (mol/L) 352.9± 115.6 336.1± 99.9 461.6± 137.8
Total cholesterol (mmol/L) 4.8± 1.1 4.9± 1.1 4.5± 1.2
Triglycerides (mmol/L) 1.6± 1.0 1.6± 1.0 1.2± 0.7
HDL (mmol/L) 1.2± 0.3 1.2± 0.3 1.1± 0.3
LDL (mmol/L) 2.9± 0.9 2.9± 0.9 2.6± 0.9
Total bilirubin (mol/L) 18.2± 9.9 17.2± 8.6 23.9± 14.1
BNP (pg/mL) 316± 153 266± 79 592± 174
Homocysteine (mg/L) 16.5± 9.3 14.4± 6.3 28.6± 13.4
hs-CRP (mol/L) 8.4± 9.8 6.4± 7.7 17.5± 14.1
Cystatin C (mg/L) 1.03± 0.47 0.91± 0.27 1.63± 0.81
Pharmacotherapy
ACE inhibitor or ARB 76 (55) 62 (53) 14 (67)
-blocker 80 (58) 67 (57) 13 (62)
Digitalis 70 (51) 57 (49) 13 (62)
Diuretic 78 (57) 64 (55) 14 (67)
Statin 68 (49) 56 (48) 12 (57)
Data are number (%) or mean± standard deviation. ACE: angiotensin-converting enzyme; ARB: angiotensin receptor blocker; BNP: B
natriuretic peptide; DCMP: dilated cardiomyopathy; HDL: high-density lipoprotein; hs-CRP: high-sensitivity C-reactive protein; LDL:
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s shown in Fig. 1A, patients with higher cystatin C levels
ad a signiﬁcantly higher adverse outcome rate compared
ith those exhibiting lower levels of cystatin C (P < 0.0001).
imilar results were observed in the analysis of the rate of
dverse outcomes based on serum hs-CRP and homocysteine
evels (Fig. 1B and C).
iscussion
eart failure has been a long-standing issue encountered
n clinical work, and it is the end stage of heart disease.
urrently, treatment methods are gradually shifting focus
rom mechanically or medically improving the activities of
he heart to eliminating the basic causes of heart failure,
n the basis of a better understanding of the underlying
echanisms [17]. Oxidative stress occurs throughout the
rogression of heart failure. Thus, certain factors have been
ssociated with prognosis. Uric acid, NT-ProBNP, creatinine,
s-CRP and cystatin C have all been shown to be predictive
f heart failure [18—21]. Cystatin C has also been observed
t increased levels during heart failure, and serves as a
a
O
bighly signiﬁcant indicator of the outcome of heart fail-
re [21]. However, these studies are rare and the follow-up
eriods are short. Furthermore, the study populations are
imited. Hence, we enrolled systolic heart failure patients
ith a wider spectrum to conduct this prospective study. Our
ntention was to carry out long-term follow-up to evaluate
hether cystatin C is associated with the prognosis of these
atients.
In the present study, two methods for evaluating the
unction of the heart were adopted: the objective measure-
ent of ejection fraction and subjective assessment of heart
unction by NYHA classiﬁcation. However, both NYHA and
jection fraction were unrelated to the adverse outcomes
bserved in the patients with heart failure. That is, although
ome patients had lower NYHA classiﬁcations and better
jection fractions, they continued to suffer from adverse
utcomes. The factors that determined the prognosis were
riglycerides, serum homocysteine, cystatin C and hs-CRP.
hs-CRP is a sensitive risk factor of inﬂammatory diseases
nd has been proven to be related to heart disease [22,23].
ther factors, such as homocysteine and cystatin C, have
een shown in recent years to have the same effect for
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Table 2 Cox univariate regression analysis.
HR (95% CI) p
Older age 2.74 (2.56—2.95) 0.805
Male sex 3.85 (3.49—7.59) 0.022
Lower LVEF 2.48 (2.27—2.78) 0.119
Higher NHYA score 1.99 (1.11—7.79) 0.703
History of hypertension 3.88 (2.80—6.42) 0.043
Diabetes 0.94 (0.86—1.10) 0.299
Atrial ﬁbrillation 2.32 (1.21—3.67) 0.818
Higher creatinine 2.67 (2.63—2.71) 0.027
Higher uric acid 2.72 (2.70—2.74) 0.859
Lower total cholesterol 1.65 (1.51—1.98) 0.178
Lower triglycerides 1.73 (1.42—2.37) 0.009
Lower HDL 1.80 (1.00—6.77) 0.339
Lower LDL 1.04 (1.00—15.91) 0.133
Higher total bilirubin 2.75 (2.61—2.91) 0.688
Higher BNP 1.12 (1.05—1.66) 0.110
Higher homocysteine 3.03 (2.79—3.30) 0.039
Higher hs-CRP 2.88 (2.72—3.06) 0.049
Higher cystatin C 3.58 (2.61—4.82) 0.033
BNP: B natriuretic peptide; CI: conﬁdence interval; HDL: high-density lipoprotein; hs-CRP: high-sensitivity C-reactive protein; HR:
hazard ratio; LDL: low-density lipoprotein; LVEF: left ventricular ejection fraction; NYHA: New York Heart Association.
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levaluating the severity of some heart diseases [8,20]. For
the prognosis of heart failure, however, reports are rare. In
the current investigation, hs-CRP was found to be related to
the prognosis of heart failure patients. Serum homocysteine
also showed a strong relationship with prognosis, and was
signiﬁcantly higher among patients experiencing adverse
outcomes during follow-up. As an essential amino acid,
homocysteine is derived from the conversion of methionine
to cysteine. Many enzymes are involved in several reactions
until methionine is eventually converted into cysteine and
vice versa. Folic acid and other B vitamins are important
co-factors; thus, serum homocysteine levels are affected by
diet. Measuring the inﬂuence of these vitamins would have
enhanced the reliability of the results of this study.
Surprisingly, cystatin C showed a considerably stronger
relationship with prognosis, indicating that it is a strong
predictor of systolic heart failure. To the best of our knowl-
edge, such a ﬁnding has not been reported thus far in the
literature. Cystatin C, which is a more sensitive marker of
renal function than creatinine, has long been used as a fac-
tor in the evaluation of renal function [24]. Thereafter,
it has been shown to be associated with the severity of
Table 3 Cox multivariable analysis.
HR (95% CI) p
Triglycerides 2.02 (1.71—2.51) 0.010
Cysteine C 7.10 (3.36—23.75) 0.006
Homocysteine 3.02 (2.88—3.17) < 0.001
hs-CRP 2.93 (2.82—3.03) < 0.001
CI: conﬁdence interval; hs-CRP: high-sensitivity C-reactive
protein; HR: hazard ratio.
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boronary artery disease and heart failure [20,25]. To the best
f our knowledge, the present study is the ﬁrst to disclose
nother function of cystatin C. Lipoproteins are associated
ith heart diseases and statin therapy is expected to reduce
he adverse outcomes of heart diseases, although the results
egarding its application in patients with established, and
articularly, advanced heart failure remain controversial
26]. For years, high low-density lipoprotein has constantly
een in the spotlight, whereas low HDL and high triglyceride
ontent are often neglected [27]. Some researchers have
eported that as a component of lipoproteins, triglyceride is
elated to the prognosis of patients with heart failure, but
ocus on this ester has not been as extensive [28]. In the
urrent work, triglyceride was found to be a predictor in
he prognosis of systolic heart failure patients. It showed an
nverse relationship with adverse outcomes among patients
ith systolic heart failure, a result that differs from that
eported in literature [28]. By looking into the data on
ipoproteins, we found that lipoprotein levels in patients
xperiencing adverse outcomes were lower than those not
uffering from adverse outcomes. Because lipoproteins are
lso sensitive to diet, we attributed this result to the poor
iet of the patients.
Bilirubin is another factor that we assumed correlated
ith the prognosis of patients with systolic heart fail-
re. A signiﬁcant difference in total bilirubin between
atients with and without adverse outcomes was observed
23.9± 14.1 vs 17.2± 8.6mol/L; P = 0.002), but in fur-
her univariate analysis, this relationship was found not
o be signiﬁcant. On the basis of our clinical experience,
atients with severe heart failure (NYHA classiﬁcations
II and IV) often have higher serum bilirubin levels than
atients with mild to moderate heart failure (20.9± 12.1 vs
5.3± 5.7mol/L; P < 0.001). Thus, we chose serum biliru-
in as a potential candidate in the prognosis of systolic heart
570
Figure 1. Cumulative proportion of patients without adverse out-
comes during follow-up (Kaplan—Meier) by levels of cystatin C (A),
hs-CRP (B) and homocysteine (C). Triangles indicate censored cases.
hs-CRP: high-sensitivity C-reactive protein.
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ailure patients. Given that the sample size is small, further
tudies including more patients would be necessary to con-
rm this ﬁnding. The same trend was also observed in the
valuation of age, uric acid and creatine. Although signif-
cant differences were exhibited between groups, further
nalysis ruled out these factors.
As inﬂammatory related diseases, hypertension and
schaemic heart disease accounted for a considerate amount
f patients in this study, 59 and 43%, respectively. Although
ypertension was signiﬁcantly predictive of adverse out-
omes in the univariate analysis, it was ruled out in the
ollowing multivariable analysis. Since the sample size was
ot large enough for this result to reach signiﬁcance on mul-
ivariable analysis, further studies with larger populations
ould be needed to clarify this matter.
onclusions
ore adverse outcomes were observed among the systolic
eart failure patients with high cystatin C levels. High serum
s-CRP and homocysteine levels were also related to the out-
omes of the patients. All of these were independent risk
actors in the prognosis of the patients with systolic heart
ailure. These results are expected to provide clinical impor-
ance in the differentiation of systolic heart failure patients
t higher risk of cardiac death, heart transplantation or pro-
ression of heart failure.
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